JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $97.00. The company’s shares opened today at $57.81.
Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, PolyPid, and Arbutus Biopharma. According to TipRanks, Buchanan has an average return of -24.5% and a 21.43% success rate on recommended stocks.
Enanta Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $73.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Enanta Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $19.48 million and a GAAP net loss of $31.7 million. In comparison, last year the company earned a revenue of $21.62 million and had a GAAP net loss of $24.02 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Most recently, in June 2022, Paul Mellett, the Treas. & CFO of ENTA bought 3,480.00 shares for a total of $40,959.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Read More on ENTA:
- Newsight Imaging to Begin Shipping the NSI9000, an Innovative Advanced Depth Sensor Chip for Automotive Lidars, Metaverse AR Glasses, Smart Cities and Other 3D Applications
- Wearable Devices (NASDAQ:WLDS) Continues Slide on Second Day of Listing
- Stock Market Today: Stocks are Up after Tuesday’s Carnage
- Haywood Keeps Their Buy Rating on Leaf Mobile Inc (EAGRF)
- Mizuho Securities Keeps Their Buy Rating on eFFECTOR Therapeutics (EFTR)
